Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder
Authors:
- 18 June 2008
- journal article
- review article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 23 (7) , 854-858
Abstract
Studies so far have provided contradictory results on immune system markers during use of antidepressants. There are no data on changes in immune parameters after treatment augmentation. The present study aimed to clarify whether the addition of bupropion in escitalopram-resistant patients with major depression causes changes in the immune system and whether treatment response could be predicted by baseline levels of cytokines. We recruited 28 depressive patients (11 men and 17 women) who did not respond to 12-week treatment with escitalopram (20 mg/d) for an augmentation trial with bupropion (150–300 mg/day). The levels of soluble interleukin-2 receptor, interleukin-8 (IL-8) and tumor-necrosis factor-α were measured before and 6 weeks after addition of bupropion. For a control group, we recruited 45 healthy volunteers (19 men and 26 women). The results indicated that the baseline levels of studied cytokines did not predict treatment response to bupropion augmentation. Concentration of IL-8 increased during the treatment similarly in both responder and non-responder groups. Although bupropion augmentation had increased the response rate in escitalopram-resistant patients, this clinical improvement was not accompanied by specific changes in studied cytokine levels.Keywords
This publication has 23 references indexed in Scilit:
- The other face of depression, reduced positive affect: the role of catecholamines in causation and cureJournal of Psychopharmacology, 2007
- Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapyJournal of Psychiatric Research, 2007
- Cytokine profiles in women with different subtypes of major depressive disorderJournal of Psychiatric Research, 2007
- Th1, Th2, and Th3 cytokine alterations in major depressionJournal of Affective Disorders, 2005
- Bupropion for fatigue and as a tumor necrosis factor-α lowering agent in primary biliary cirrhosisMedical Hypotheses, 2005
- Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or VenlafaxinePharmacopsychiatry, 2002
- Anti-Inflammatory Effects of Antidepressants Through Suppression of the Interferon-γ/Interleukin-10 Production RatioJournal of Clinical Psychopharmacology, 2001
- Cytokine Production and Treatment Response in Major Depressive DisorderNeuropsychopharmacology, 2000
- Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remissionEuropean Archives of Psychiatry and Clinical Neuroscience, 1997
- Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depressionJournal of Affective Disorders, 1995